Valeant Pharmaceuticals (VRX) Stock: Climbing on Takeover Rejection!

Valeant Pharmaceuticals Intl Inc (NYSE: VRX)

Valeant Pharmaceuticals is having an incredibly strong day in the market today, and for good reason. News surfaced that the company has made the decision to decline a joint takeover bid. Today, we’ll talk about the details of the bid, how the market reacted to the news, and what we can expect to see from VRX moving forward. So, let’s get right to it…

VRX Rejects Takeover Bid

For some time now, Valeant Pharmaceuticals has been struggling. However, at this point, the company is on a clear path to recovery. So, it’s no surprise that we’re starting to see takeover bids. Recently, a biotechnology company out of Japan, Takeda Pharmaceutical, and a private-equity firm known as TPG, made an offer to takeover the company. If the takeover were successful, Takeda would focus on Salix Pharmaceuticals while TPG would handle the rest. However, VRX made the decision to reject the offer.

While the takeover bid didn’t come with a firm price, it seems as though VRX wouldn’t be willing to sell at just about any reasonable price at the moment. In fact, Mizuho analyst, Irina Koffer, said that she doesn’t think the larger shareholders are willing to part with the stock at the moment. This is even if a strong premium were offered. Here’s what she had to say…

We think that large shareholders and Valeant Board members are so far underwater on their positions that they may be resistant to a potential bid which may “undervalue” the company…”

How The Market Reacted To The News

As investors, we know that the news moves the market. Any time there is positive news associated with a publicly traded company, we can expect to see gains in that company’s stock as a result. Adversely, negative news will generally cause declines. In this particular case, the news was overwhelmingly positive. First and foremost, investors tend to get excited when takeover bids are offered. However, in this particular case, the news that the company declined the bid is even more positive. The reality is that VRX has fallen dramatically, and many investors believed that declines would continue. If the management of the company felt the same, they would have sold out quickly. However, Valeant isn’t ready for that, they see more gains coming. As a result, we’re seeing strong movement in the value of the stock today. Currently (10:40), VRX is trading at $28.93 per share after a gain of $1.99 per share or 7.39% thus far today.

What We Can Expect To See Moving Forward

Over the past month or so, I have been very forthcoming about my bullish opinion on VRX. The reality is that the company fell on an incredibly hard time. It had to deal with a scandal going public, which caused the loss of its biggest customer. However, in the months following the scandal, we’ve seen incredible positivity. The company has switched out it’s CEO, added members to its Board of Directors, and even signed a contract with Walgreens for the sale of its treatments. While I know that it’s going to take quite a while for investors to become confident in the stock once again, it’s clear to me at this point that VRX is incredibly undervalued. The reality is that the company has made it over the hurdle and is now once again moving forward. As a result, I’m expecting to see gains in the value of the stock moving forward.

What Do You Think?

Where do you think VRX is headed moving forward and why? Let us know your opinion in the comments below!